We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $67.38, moving -0.24% from the previous trading session. This change lagged the S&P 500's daily gain of 0.11%. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.19%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 8.01% in the past month. In that same time, the Medical sector gained 1.2%, while the S&P 500 gained 3.84%.
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date. This is expected to be May 2, 2019. The company is expected to report EPS of $1.61, up 8.78% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.29 billion, up 4.03% from the year-ago period.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.64 per share and revenue of $22.01 billion. These results would represent year-over-year changes of -0.45% and -0.55%, respectively.
It is also important to note the recent changes to analyst estimates for GILD. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD is currently a Zacks Rank #4 (Sell).
Digging into valuation, GILD currently has a Forward P/E ratio of 10.16. This represents a discount compared to its industry's average Forward P/E of 21.48.
It is also worth noting that GILD currently has a PEG ratio of 3.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.04 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $67.38, moving -0.24% from the previous trading session. This change lagged the S&P 500's daily gain of 0.11%. Elsewhere, the Dow lost 0.32%, while the tech-heavy Nasdaq added 0.19%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 8.01% in the past month. In that same time, the Medical sector gained 1.2%, while the S&P 500 gained 3.84%.
Wall Street will be looking for positivity from GILD as it approaches its next earnings report date. This is expected to be May 2, 2019. The company is expected to report EPS of $1.61, up 8.78% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.29 billion, up 4.03% from the year-ago period.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.64 per share and revenue of $22.01 billion. These results would represent year-over-year changes of -0.45% and -0.55%, respectively.
It is also important to note the recent changes to analyst estimates for GILD. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD is currently a Zacks Rank #4 (Sell).
Digging into valuation, GILD currently has a Forward P/E ratio of 10.16. This represents a discount compared to its industry's average Forward P/E of 21.48.
It is also worth noting that GILD currently has a PEG ratio of 3.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 2.04 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.